Market Overview

UPDATE: Morgan Stanley Reiterates on Verisk Analytics on Buying Opportunity After Soft Q4

Share:
Related VRSK
Earnings Scheduled For August 2, 2016
Analysts At BMO Capital Give Investors Their Picks In 4 Sectors
Cotivity Is A Good Play On Increasing Complexity In Managing Healthcare (Seeking Alpha)

In a report published Thursday, Morgan Stanley analyst Suzanne E. Stein reiterated an Overweight rating on Verisk Analytics (NASDAQ: VRSK), but lowered the price target from $74.00 to $73.00.

In the report, Morgan Stanley noted, “Shares fell on slowing insurance revenue growth and flat margins in Risk Assessment, but we see this as a buying opportunity. Healthcare and Specialized markets improved after negative commentary last quarter, but Insurance (in Decision Analytics) is an open question for 2014. Despite the deceleration in this segment to 7.3% y/y in Q4 from the 8-9% level earlier in the year, we believe revenue should accelerate in F14 due to cross-selling, a healthier P&C market, and eventual synergies from the EVT deal. Furthermore, we expect healthcare margins will improve as it scales. We trimmed our EPS forecast and price target to reflect the sale of Interthinx and the Insurance slowdown, and maintain an Overweight rating.”

Verisk Analytics closed on Wednesday at $63.78.

Latest Ratings for VRSK

DateFirmActionFromTo
Aug 2016MacquarieInitiates Coverage onNeutral
Aug 2016UBSMaintainsSell
Mar 2016Sterne Agee CRTInitiates Coverage onNeutral

View More Analyst Ratings for VRSK
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Suzanne E. SteinAnalyst Color Price Target Analyst Ratings

 

Related Articles (VRSK)

View Comments and Join the Discussion!